Clinical Trials
79 trialsAutologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Institutes of Health Clinical Center (CC)
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
Huahui Health
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
Hangzhou DAC Biotechnology Co., Ltd.
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Safety and Preliminary Activity of BI115 in Advanced SCLC
Innovent Biologics (Suzhou) Co. Ltd.
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Moonlight Bio, Inc
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Dana-Farber Cancer Institute
COMETH
University of Kansas Medical Center
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Shanghai Best-Link Bioscience, LLC
T-BRAIN
Maastricht University Medical Center
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC
Shanghai Pulmonary Hospital, Shanghai, China
A Lay Navigation Intervention for Patients With Lung Cancer
University Health Network, Toronto
DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
Washington University School of Medicine
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Sichuan Baili Pharmaceutical Co., Ltd.
Aurora004
Shanghai Pulmonary Hospital, Shanghai, China
Aurora 005
Shanghai Pulmonary Hospital, Shanghai, China
STAR-01
Sichuan University
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
The Affiliated Hospital of Qingdao University
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
ALISCA-Lung2
Puma Biotechnology, Inc.
SCLC Tarlatamab Blood Collection
Duke University
A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
Shanghai Best-Link Bioscience, LLC
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
The Third Affiliated Hospital of Harbin Medical University
SKB264-ANLO
China Medical University, China
Lung Cancer Screening in Population Who Had Never Smoked
Chung Shan Medical University
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Peking University Cancer Hospital & Institute
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
LOTS
Indiana University
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
Shanghai Henlius Biotech
Penfluridol for Relapsed/Refractory Small Cell Cancers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
Peking University Cancer Hospital & Institute
A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors
Tianjin First Central Hospital
Prospective Observational Study on ES-SCLC
Peking Union Medical College Hospital
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
Biotroy Therapeutics
Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer
Peking Union Medical College Hospital
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
Sun Yat-sen University
A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)
Addario Lung Cancer Medical Institute
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
West China Hospital
PPI-PROTECT
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
Fujian Cancer Hospital
STAR-SCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Safety Study of 212Pb-Pentixather Radioligand Therapy
University of Iowa
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
PASSIFLORE
Institut Cancerologie de l'Ouest
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
Changchun GeneScience Pharmaceutical Co., Ltd.